Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy
Our study highlights the critical role of dynamic changes within the tumor immune microenvironment in predicting the efficacy of neoadjuvant combined immunochemotherapy. We examined the disparities between MPR/non-MPR groups, shedding light on potential mechanisms of immune response and suppression. In addition to bolstering cytotoxic immune responses, specifically targeting Treg cells may be crucial for enhancing treatment outcomes.
Authors
- Yong Liu (ORCID: https://orcid.org/0000-0001-7395-4153)
- Yi Ba
- Li Su (ORCID: https://orcid.org/0000-0003-1142-0505)
- Daniel Zuo (ORCID: https://orcid.org/0000-0003-2814-6901)
- Le Zhang (ORCID: https://orcid.org/0000-0002-3708-1727)
- Yanhui Zhang (ORCID: https://orcid.org/0000-0002-3825-2049)
- Hongli Li (ORCID: https://orcid.org/0009-0000-9450-387X)
- Xia Wang (ORCID: https://orcid.org/0000-0002-6791-4072)
- Rui Liu (ORCID: https://orcid.org/0000-0002-2262-5525)
- Ting Deng (ORCID: https://orcid.org/0000-0001-5477-7972)
- Tingting Ding (ORCID: https://orcid.org/0000-0003-2836-0086)
- Zhi Ji (ORCID: https://orcid.org/0000-0001-8243-5187)
- Xinze Lv
- Jiaqi Xin (ORCID: https://orcid.org/0009-0003-2729-3181)
- Lijun Ma (ORCID: https://orcid.org/0000-0002-8423-8483)
- Shaohua Ge
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Burning Rock Biotech (China) (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-010041
- Citations
- 13
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.67
Funders
- Tianjin Medical University
- Wu Jieping Medical Foundation
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Bijzonder Onderzoeksfonds UGent